Neratinib: Inching up on the cure rate of HER2+ breast cancer?

Nisha Unni; Dhivya R. Sudhan; Carlos L. Arteaga

doi:10.1158/1078-0432.CCR-18-1114

Neratinib: Inching up on the cure rate of HER2⁺ breast cancer?

Nisha Unni, Dhivya R. Sudhan, Carlos L. Arteaga

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2⁺ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER⁺)/ HER2⁺ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.

Original language	English (US)
Pages (from-to)	3483-3485
Number of pages	3
Journal	Clinical Cancer Research
Volume	24
Issue number	15
DOIs	https://doi.org/10.1158/1078-0432.CCR-18-1114
State	Published - Aug 1 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-18-1114

Cite this

@article{34889745bb2944ab93fffcb42a4cdbe3,

title = "Neratinib: Inching up on the cure rate of HER2+ breast cancer?",

abstract = "Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.",

author = "Nisha Unni and Sudhan, {Dhivya R.} and Arteaga, {Carlos L.}",

note = "Publisher Copyright: {\textcopyright} 2018 American Association for Cancer Research.",

year = "2018",

month = aug,

day = "1",

doi = "10.1158/1078-0432.CCR-18-1114",

language = "English (US)",

volume = "24",

pages = "3483--3485",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "15",

}

TY - JOUR

T1 - Neratinib

T2 - Inching up on the cure rate of HER2+ breast cancer?

AU - Unni, Nisha

AU - Sudhan, Dhivya R.

AU - Arteaga, Carlos L.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.

AB - Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.

UR - http://www.scopus.com/inward/record.url?scp=85051132499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051132499&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1114

DO - 10.1158/1078-0432.CCR-18-1114

M3 - Article

C2 - 29802101

AN - SCOPUS:85051132499

SN - 1078-0432

VL - 24

SP - 3483

EP - 3485

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 15

ER -

Neratinib: Inching up on the cure rate of HER2⁺ breast cancer?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this